TGFB1 and neoplasm: This could be achieved by converting tumour-promoting CAFs into a more tumour-suppressive phenotype, ablation of a tumour-promoting population, targeting of specific tumour-promoting secreted chemokines or cytokines, such as TGFβ, or by a combination of these approaches.